For example, the synergy predictions associated with the breast cancer cell line JIMT1 (breast ductal adenocarcinoma) and the drug MK-2206, a highly selective inhibitor of Akt1/2/3, has among the top 5 scoring GO categories the GO:0007169 (transmembrane receptor protein tyrosine kinase signaling pathway) and the GO:0007584 (response to nutrient). Here, AKT1 is linked to breast cancer.